[fusion_builder_container hundred_percent=”yes” overflow=”visible”][fusion_builder_row][fusion_builder_column type=”2_3″ spacing=’yes’ last=’no’ background_color=” background_image=” background_repeat=’no-repeat’
background_position=’left top’ border_size=’0px’ border_color=” border_style=’solid’ padding=” class=” id=”]

News5050 – Company Report

April 11, 2017

[/fusion_builder_column][fusion_builder_column type=”1_3″ spacing=’yes’ last=’yes’ background_color=” background_image=” background_repeat=’no-repeat’ background_position=’left top’ border_size=’0px’ border_color=” border_style=’solid’ padding=” class=” id=”][fusion_button link=’https://www.researchandexperts.com/Canada/life-sciences/report/05IC-GDPH510049D/’ color=’orange’ size=’large’ type=’flat’ shape=’pill’ target=’_blank’ title=’Innovative Targeting Solutions Inc – Pharmaceuticals & Healthcare…’ gradient_colors=’|’ gradient_hover_colors=’|’ accent_color=” accent_hover_color=” bevel_color=” border_width=’1px’ shadow=” icon=’fa-search’ icon_divider=’yes’ icon_position=’left’ modal=” animation_type=’0′ animation_direction=’down’ animation_speed=’0.1′ alignment=’left’ class=” id=”]View report[/fusion_button][/fusion_builder_column]

The Report:

Innovative Targeting Solutions Inc (ITS) focuses on the development of novel human antibody technologies. The company developed a next generation protein engineering platform which helps for the generation of fully human antibody and T cell receptor based therapeutics using its proprietary HuTARG technology. ITS’s utilizes its technology to develop its pipeline programs such as agonists, rare epitopes, complex membrane proteins for various therapeutic areas. HuTARG technology, is a fully mammalian technology which generates antibody diversity in vitro via RAG1/RAG2 mediated V(D)J recombination. The company conducts research collaborations with other organizations such as Merck; Amgen and Novartis, among others to identify and develop novel biologic therapeutic candidates. ITS is headquartered in Burnaby, British Columbia, Canada.

Scope

Scope

– Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
– Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
– Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
– Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
– Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
– Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
– Business Description – A brief description of the company’s operations.
– Key Employees – A list of the key executives of the company.
– Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
– Key Competitors – A list of the key competitors of the company.
– Key Recent Developments – A brief on recent news about the company.

About Research and Experts:

Research and Experts brings you to the latest reports in market research on Life Sciences and much more.

Contact:

John Caldwell

Fia Rua, Deerpark

Bunratty, Co. Clare, Ireland

Check out Market Reports at www.researchandexperts.com

News5050 - ResearchandExperts


Report: REP000287378[/fusion_builder_row][/fusion_builder_container]